Controversy has broken out in India regarding access to two treatments that are used to address drug resistant tuberculosis (TB). The medications, bedaquiline and delamanid are all but unavailable in India, with fewer than 1,000 DR-TB patients in India receiving bedaquiline and only 81 receive delamanid. This has led to calls for the issuing of … [Read more...] about TB ‘miracle cures’ and the issue of high expectations
India holds a unique position in the generic market. Commonly referred to as the “pharmacy of the developing world”, India exports huge volumes of generic medication. This forms a multi-billion dollar industry within India. This low cost generics market has improved access to lower price medications in India, as well as allowed for the export … [Read more...] about Indian patent laws, no longer the pharmacy of the developing world?
A hard Brexit could be good news for the tobacco industry, warns an anti-smoking charity in Scotland. The warning comes amidst fears the UK government and tobacco companies - particularly British American Tobacco (BAT) - are becoming a little too close for comfort. Vulnerable to tobacco lobbying ASH Scotland has told a committee they are … [Read more...] about Brexit: A boon for Big Tobacco?
Early-stage human trials have shown that a potential treatment for Huntington’s disease -- devised by University College London -- is both safe and potentially effective. But is it a “breakthrough that may stop the disease” that media reports claim? Huntington's disease, as of yet, has no cure. IONIS-HTTRx, a potential cure? The potential new … [Read more...] about New hope for Huntington’s disease?
In yet another setback to the treatment of Alzheimer’s disease, Axovant Sciences has announced that their latest attempt at creating a treatment - a drug known as Intepirdine (a (5-HT)6 receptor antagonist) - has failed during late stage clinical trials. Meanwhile, pharmaceutical giant Pfizer Inc has announced plans to leave the field of … [Read more...] about Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research
A robotic takeover has long been thought of as the stuff of nightmares, from being a staple of science fiction doomsday scenarios to being warned of by sci-tech leaders such as Elon Musk as an outcome if artificial intelligence (AI) technology continues to grow. In contrast to these bleak predictions on the future of robotics, however, the … [Read more...] about Robotic takeover of healthcare on the horizon?
Alzheimer’s research may see a well needed boost in the form of a research deal funded by Chicago based pharmaceutical group AbbVie. The recipient research group, Alector, is to receive a $205 million USD up front payment, as well as future equity investments worth up to $20 million. Alector has seen a great deal of interest within the … [Read more...] about Immunotherapy: the future of Alzheimer’s research?
Children in Africa have shown a prevalence of up to 54 percent of HIV strains which display a resistance to one or more commonly used antiretroviral (ARV) drugs according to a study published in Clinical Infectious Diseases. Is this an indication that currently used medications may prove to be ineffective in years to come? Africa has seen a … [Read more...] about Drug resistant HIV and the potential to render current treatments inviable
In 2016 an event took place in global health which failed to make major headlines. Over a two week period over 150 countries simultaneously changed their currently used polio vaccines to one deemed more efficient. The move is a demonstration of the concerted efforts of countries across the globe - and a testament to the efficiency and … [Read more...] about The continued fight against polio
The UK government has put forward ambitious plans for the pharmaceutical industry since Brexit. Though seemingly enterprising, there are worries that these plans simply appear promising on paper and do not have enough resources to see them through. Brexit has been marred by uncertainty since the UK voted to leave the European Union. The prospect … [Read more...] about Ambitious goals for UK Pharma, does the budget match up?